Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Material Agreement (Jul 2, 2026)

Reports
Material Agreements·Securities & Listing·Shareholder Matters+3
Filing Date
Filed July 2, 2026
Period End
July 1, 2026
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 8-K filed July 2, 2026. Cited figures are marked; the original filing is the authoritative source.

On July 1, 2026, BridgeBio Pharma, Inc. (Nasdaq: BBIO) entered into an Investment Agreement with purchasers including Chinotto Investments, LLC (a Sixth Street entity) and HCRx Investments HoldCo, L.P.

(an affiliate of KKR's HealthCare Royalty), issuing 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock at $1,000a per share for an aggregate purchase price of $933.9 million. Sixth Street purchased 800,000 shares ($800.0 million) and HCRx purchased 133,900 shares ($133.9 million). Sixth Street or its affiliates also have a right, subject to Board approval, to provide up to an additional $66.1 million on substantially identical terms, bringing the total potential investment to $1.0 billion.

The filing notes that HCRx is affiliated with KKR, a holder of more than 5%b of the Company's Common Stock, and that director Ali Satvat is a partner there. The Preferred Stock ranks senior to common stock on dividends and liquidation. It accrues dividends at 7.00% per annum, payable quarterly in cash or compounded into the Accumulated Amount at the Company's option, with step-ups including 500 basis points on the seventh anniversary of the July 1, 2026 issuance date, and a cap of 17.00%.

Initial conversion price is $137.79 per share, rising to $153.10c on the fifth anniversary. The initial purchased shares are convertible into 6,777,705 shares of Common Stock. Holders have no redemption right at their option; the Company may redeem from the third anniversary onward at a formula-based price, and conversion is subject to a 19.9% beneficial ownership limitation until stockholder approval is obtained.

The Company has agreed to seek that approval at its 2027 annual meeting or a special meeting no later than June 30, 2027, if required by Nasdaq rules. The issuance dilutes common holders' economic and voting rights, as the Preferred Stock votes with common on an as-converted basis and carries separate class consent rights over certain actions, including incurring certain indebtedness and making certain restricted payments. The Company's press release characterizes the transaction as a $1 billiond financing to support launches of Attruby and three additional U.S. product candidates (BBP-418, encaleret and infigratinib) over the next 12 months.

Key Highlights

  1. Issued 933,900 Series A Cumulative Convertible Participating Preferred Shares at $1,000 per share for $933.9 million, with Sixth Street funding $800.0 million and HCRx funding $133.9 million.
  2. Sixth Street or its affiliates have an option, subject to Board approval, to invest up to an additional $66.1 million on substantially identical terms.
  3. Preferred Stock accrues dividends at 7.00% per annum, payable in cash or compounded at the Company's option, with step-ups including a 500 basis point increase on the seventh anniversary and a 17.00% cap.
  4. Initial conversion price of $137.79 per share, increasing to $153.10 after the fifth anniversary; purchased shares are initially convertible into 6,777,705 common shares.
  5. Company may redeem from the third anniversary onward at a formula-based price, with a 13% internal rate of return floor applying on or after the seventh anniversary; holders cannot require redemption.
  6. HCRx is affiliated with KKR, a holder of more than 5% of common stock, and director Ali Satvat is a partner there, making this a related-party transaction.
  7. The Preferred Stock ranks senior to common stock and carries class consent rights over certain indebtedness, restricted payments and senior or parity securities, while the 2027 stockholder approval covers Nasdaq-required conversion without the 19.9% limitation.

Frequently Asked Questions

  1. How much capital did BridgeBio raise and from whom?

    BridgeBio issued 933,900 shares of Series A Preferred Stock at $1,000 per share, for $933.9 million in total. Sixth Street purchased 800,000 shares for $800.0 million and HCRx, an affiliate of KKR, purchased 133,900 shares for $133.9 million. Sixth Street or its affiliates may invest up to an additional $66.1 million, subject to Board approval, bringing the potential total to $1.0 billion.

  2. What are the key economic terms of the Preferred Stock?

    The Preferred Stock accrues dividends at 7.00% per annum, payable quarterly in cash or added to the Accumulated Amount at the Company's option. The rate can increase by 500 basis points on the seventh anniversary, by 125 basis points periodically after the eighth anniversary up to a 17.00% cap, by 300 basis points during a Triggering Event, and by 200 basis points in certain change of control transactions where the preferred is not redeemed. Preferred holders also participate in common dividends on an as-converted basis.

  3. How could this financing dilute existing common stockholders?

    The purchased shares are initially convertible into 6,777,705 common shares at $137.79 per share, rising to $153.10 after the fifth anniversary, subject to anti-dilution adjustments. Preferred holders vote with common stockholders on an as-converted basis, subject to a 19.9% beneficial ownership limit until stockholder approval is obtained. The Preferred Stock also ranks senior to common stock on dividends and liquidation, and common dividends and repurchases are restricted unless preferred participation is paid.

  4. Can investors force the Company to redeem the Preferred Stock?

    No. The Preferred Stock is not redeemable at the option of holders. The Company may redeem all or part of the outstanding shares after the third anniversary of the Original Issuance Date at the greatest of an as-converted value, a premium of 120% of the original issue price plus accrued balance (rising to a maximum of 140%), or a 13% internal pre-tax rate of return amount in certain circumstances. The Company may also require conversion if the common stock trades above 200% of the conversion price under specified conditions.

  5. What does the press release say about the purpose of the financing?

    The press release, filed as Exhibit 99.1, says the financing strengthens the balance sheet and supports launches of Attruby, which it describes as continuing to grow into a multi-billion-dollar drug, as well as three additional potential U.S. launches over the next 12 months: BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigratinib for achondroplasia.